クラドリビン
”. Journal of Neurology 265 (5): 1199–1209. doi:10.1007/s00415-018-8830-y. PMC 5937883. PMID 29550884. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937883/.
1 2 Giovannoni, G; Soelberg Sorensen, P; Cook, S; Rammohan, K; Rieckmann, P; Comi, G; Dangond, F; Adeniji, AK et al. (1 August 2017). “Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.”. Multiple Sclerosis (Houndmills, Basingstoke, England) 24 (12): 1594–1604. doi:10.1177/1352458517727603. PMID 28870107. オリジナルの10 March 2020時点におけるアーカイブ。. https://web.archive.
1001/jamaneurol.2017.0676. PMC 5710323. PMID 28604916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710323/.
↑ “Cladribine tablets for treating relapsing–remitting multiple sclerosis”. National Institute for Clinical Excellence. 2018年9月23日閲覧。
↑ Hasanali, Zainul S.; Saroya, Bikramajit Singh; Stuart, August; Shimko, Sara; Evans, Juanita; Shah, Mithun Vinod; Sharma, Kamal; Leshchenko, Violetta V. et al. (24 June 2015). “Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia”. Science Translational Medicine 7 (293): 293ra102. doi:10.1126/scitranslmed.aaa5079. ISSN 1946-6234. PMC 4807901. PMID 26109102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807901/.